Rhythm Pharmaceuticals
151 articles about Rhythm Pharmaceuticals
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - May 5, 2023
5/5/2023
Rhythm Pharmaceuticals, Inc. today announced that on May 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 76,440 shares of its common stock to 16 new employees.
-
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
4/24/2023
Rhythm Pharmaceuticals, Inc. today announced the commercial launch of IMCIVREE ® (setmelanotide) in Germany for the treatment of obesity and control of hunger associated with Bardet-Biedl syndrome (BBS).
-
Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
4/18/2023
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 2, 2023 to report its first quarter 2023 financial results and provide a corporate update.
-
Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
4/10/2023
Rhythm Pharmaceuticals, Inc. today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - April 06, 2023
4/6/2023
Rhythm Pharmaceuticals, Inc. announced that on April 4, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 21,870 shares of its common stock to three new employees, consisting of inducement stock options to purchase an aggregate of 14,580 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 7,290 shares of its common stock.
-
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
3/27/2023
Rhythm Pharmaceuticals, Inc. announced the publication of interview-based patient and caregiver reported experiences of hunger and quality of life with setmelanotide treatment in Bardet-Biedl syndrome.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - March 6, 2023
3/6/2023
Rhythm Pharmaceuticals, Inc. today announced that on March 1, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 34,215 shares of its common stock.
-
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
3/1/2023
Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2022.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - February 8, 2023
2/8/2023
Rhythm Pharmaceuticals, Inc. today announced that on February 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 24,525 shares of its common stock.
-
Rhythm Pharmaceuticals published data Monday showing Imcivree (setmelanotide) improved quality of life for patients with obesity related to Bardet-Biedl Syndrome.
-
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
7/28/2022
Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 2, 2022 to report its second quarter 2022 financial results and provide a corporate update.
-
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome
7/22/2022
Rhythm Pharmaceuticals, Inc. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE.
-
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France
7/20/2022
Rhythm Pharmaceuticals, Inc. today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) have granted pre-marketing authorization AP1 (autorisation d’accès précoce - early access authorization),
-
The FDA approved Rhythm Pharmaceutical’s Imcivree (setmelanotide) for patients with Bardet-Biedl syndrome.
-
Versanis Bio's data reveals the results of a pooled analysis, showing that its lead asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.
-
Rhythm Pharmaceuticals Presents New Data from Long-term Extension Trial Evaluating Setmelanotide in Bardet-Biedl Syndrome or POMC or LEPR Deficiency Obesity at ENDO 2022
6/13/2022
Rhythm Pharmaceuticals, Inc. today announced new data from the Company’s long-term extension (LTE) trial, which show continued body mass index (BMI) and weight reductions in patients with Bardet-Biedl syndrome (BBS) or POMC or LEPR deficiency obesity (biallelic) receiving between 18 months and three years of setmelanotide therapy.
-
Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
-
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
5/5/2022
Rhythm Pharmaceuticals, Inc. today announced that on May 3, 2022, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 50,730 shares of its common stock to 10 new employees.
-
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
5/3/2022
Rhythm Pharmaceuticals, Inc. today reported financial results and provided a business update for the first quarter ended March 31, 2022.
-
Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
4/26/2022
Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 3, 2022 to report its first quarter 2022 financial results and provide a corporate update.